阿拉伯树胶（）在II期试验中增强血液透析患者的总抗氧化能力并降低C反应蛋白。

Gum Arabic () Augmented Total Antioxidant Capacity and Reduced C-Reactive Protein among Haemodialysis Patients in Phase II Trial.

作者信息

Ali Nour Elkhair, Kaddam Lamis AbdelGadir, Alkarib Suad Yousif, Kaballo Babikir Gabir, Khalid Sami Ahmed, Higawee Abdalazim, AbdElhabib Alaa, AlaaAldeen Alaa, Phillips Aled O, Saeed Amal Mahmoud

机构信息

Department of Physiology, Faculty of Medicine, Alneelain University, Khartoum, Sudan.

Nephrology Unit, Military Hospital Omdurman, Sudan.

出版信息

Int J Nephrol. 2020 Apr 9;2020:7214673. doi: 10.1155/2020/7214673. eCollection 2020.

BACKGROUND

Oxidative processes might increase in patients with end-stage renal disease (ESRD) according to the current literature. Oxidative stress (OS) is a risk factor of atherosclerosis and cardiovascular complications, which are major causes of mortality among ESRD patients. Haemodialysis (HD) is life-saving procedure, nevertheless it is an active chronic inflammatory status that could augment cardiovascular disease and increase mortality. Gum Arabic (GA) has been claimed to act as an antioxidant and anti-inflammatory agent in experimental studies and clinical trials. Therefore, we assumed GA supplementation among haemodialysis patients would reduce oxidative stress and consequently reduce the state of chronic inflammatory activation associated with haemodialysis.

METHODS

Forty end-stage renal failure (ESRF) patients aged 18-80 years who were on regular haemodialysis in Arif Renal Center, Omdurman, Sudan, were recruited. All recruited patients met the inclusion criteria and signed informed consent prior to enrolment. The patients received 30 g/day of GA for 12 weeks. C-reactive protein (CRP) and complete blood count (CBC) were measured as baseline and monthly. Total antioxidant capacity (TAC) and oxidative stress marker malondialdehyde (MDA) levels were measured before and after GA intake. Ethical approval from the National Medicines and Poisons Board was obtained.

RESULTS

Gum Arabic significantly augmented total antioxidant capacity level ( < 0.001) (95% CI, 0.408-0.625) and also attenuated oxidative marker MDA and C-reactive protein ( < 0.001).

CONCLUSIONS

GA has revealed potent antioxidative and anti-inflammatory properties in haemodialysis patients. Oral digestion of GA (30 g/day) decreased oxidative stress and inflammatory markers among haemodialysis patients. Trial registration. ClinicalTrials.gov Identifier: NCT03214692, registered 11 July 2017 (prospective registration).

背景

根据当前文献，终末期肾病（ESRD）患者的氧化过程可能会增加。氧化应激（OS）是动脉粥样硬化和心血管并发症的危险因素，而这些并发症是ESRD患者死亡的主要原因。血液透析（HD）是一种挽救生命的治疗方法，但它是一种活跃的慢性炎症状态，可能会加剧心血管疾病并增加死亡率。在实验研究和临床试验中，阿拉伯胶（GA）被认为具有抗氧化和抗炎作用。因此，我们推测在血液透析患者中补充GA可降低氧化应激，从而减轻与血液透析相关的慢性炎症激活状态。

方法

招募了苏丹恩图曼阿里夫肾脏中心40名年龄在18至80岁之间、正在接受定期血液透析的终末期肾衰竭（ESRF）患者。所有招募的患者均符合纳入标准，并在入组前签署了知情同意书。患者每天服用30克GA，持续12周。在基线时和每月测量C反应蛋白（CRP）和全血细胞计数（CBC）。在摄入GA前后测量总抗氧化能力（TAC）和氧化应激标志物丙二醛（MDA）水平。获得了国家药品和毒物管理局的伦理批准。